FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment

Completed · Phase 4

Conditions studied: HIV Infections

In brief

For people with HIV who are currently taking specific medications (including Sustiva (efavirenz)) and have no detectable viral load, this study tracks how patients do if they take their medications for five days of the week compared with seven days of the week.

Key facts

Study ID

NCT00414635

Run by

Community Research Initiative of New England

People needed

60

Starts

2006-08-01

Expected to finish

2009-12-01

Last updated by the study team

2017-09-25

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years or older
• CD4 count > or = 200
• Viral load < 50
• Treatment with a regimen containing efavirenz and tenofovir and lamivudine or emtricitabine for at least 90 days prior to screening

You may not qualify if…

• Detectable HIV RNA on an ultrasensitive assay within the 90 days preceding screening
• Prior evidence of intermediate or high level resistance to efavirenz, tenofovir or cytidine analogues
• Hepatitis B infection

Where it is running

• Whitman-Walker Clinic — Washington D.C., District of Columbia, United States
• CARE-ID — Washington D.C., District of Columbia, United States
• Steinhart Medical Associates — Miami, Florida, United States
• Orlando Immunology Center — Orlando, Florida, United States
• Treasure Chest Infectious Disease — Vero Beach, Florida, United States
• Community Research Initiative of New England - Boston — Boston, Massachusetts, United States
• Community Research Initiative of New England - West — Springfield, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.